Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 137)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 5
Gesamt: 390.068
Gesamt: 390.068
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BVF
6,3420
EUR
-2,60 %
-0,1690 EUR
Letzter Kurs 17.05.24 Tradegate
Neuigkeiten
17.05.24 · Accesswire |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
0,8000 | +45,45 | |
1,0000 | +42,86 | |
3,0000 | +42,18 | |
6,2500 | +24,75 | |
0,9600 | +18,93 |
Wertpapier | Kurs | Perf. % |
---|---|---|
114,60 | -13,61 | |
23,700 | -19,52 | |
28,60 | -24,06 | |
1,3500 | -25,62 | |
0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Francis Chou Nearly Dumps Entire Stake in Valeant, Teva and Overstock in 4th Quarter
https://www.gurufocus.com/news/642651/francis-chou-nearly-du…...
Chou axed 95.12% of his Valeant stake, selling 2,904,851 shares for an average price of $15.84. With this transaction, the manager knocked 14.8% off his portfolio.
War wohl etwas zu früh?
Zufälle gibt es...
Antwort auf Beitrag Nr.: 57.045.360 von marty44 am 16.02.18 16:44:51Man strebt offensichtlich an, diese hemmende Black Box Warnung los zu werden. Toi Toi kann man da nur wünschen. Ich hab anfang der Woche auch aufgestockt. Zwar nicht so viel wie Renaissance Tech. LLC aber für meine Verhälnisse doch recht deutlich.
VRX Crosses Above Average Analyst Target
https://www.nasdaq.com/article/vrx-crosses-above-average-ana…
https://www.newswire.ca/news-releases/ortho-dermatologics-pr…
Separate Phase 3 Analysis Highlights Long-Term Safety Profile of SILIQ
LAVAL, Quebec, Feb. 16, 2018 /CNW/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX), today announced results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the first time at the 76th Annual Meeting of the American Academy of Dermatology (AAD), Feb. 16-20, 2018, in San Diego.
Ortho Dermatologics Presents An Analysis Of SILIQ™ (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
Summary of Results
Effects of Brodalumab on Anxiety and Depression in Patients With Psoriasis: Results From a Phase 3, Randomized, Controlled Clinical Trial
Results from the Phase 3, randomized, controlled clinical trial AMAGINE-1 suggested that treatment with SILIQ reduced anxiety and depression in patients with moderate-to-severe plaque psoriasis. In the study, hospital anxiety and depression scale (HADS) scores were measured at baseline and at 12, 24, 36 and 52 weeks in patients treated with SILIQ (210 mg) or placebo. After 12 weeks of SILIQ treatment, patients experienced a decrease in depression and anxiety HADS scores (mean scores decreased by 2.1 and 1.8, respectively) while scores remained unaffected in those receiving placebo. Improvement in depression and anxiety HADS scores were also seen in patients who switched from placebo to SILIQ after a 12 week induction phase (mean scores decreased by 2.3 and 1.7, respectively), but worsened in patients who switched from SILIQ to placebo.
Long-term Safety of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: 2-Year Data From 3 Pivotal Phase 3 Clinical Trials
Results from a pooled analysis of three double-blind, placebo-controlled, Phase 3 clinical trials (AMAGINE-1, -2, and -3) demonstrated that the safety profile of SILIQ in patients with moderate-to-severe plaque psoriasis during the second year of treatment was similar to that of the first year of treatment. Additionally, no unexpected safety signals emerged. The analysis evaluated 3,708 patients who received any dose of SILIQ in the long-term, open-label extension studies of the three trials. Overall, in the second year of treatment, the most common treatment-emergent adverse events were joint pain (n=196), headache (n=155) and candida infections (n=111), and one fatal treatment-emergent adverse event (cardiac arrest) occurred.
Eigentlich müßte das Black Label nun entfallen!
Separate Phase 3 Analysis Highlights Long-Term Safety Profile of SILIQ
LAVAL, Quebec, Feb. 16, 2018 /CNW/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX), today announced results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the first time at the 76th Annual Meeting of the American Academy of Dermatology (AAD), Feb. 16-20, 2018, in San Diego.
Ortho Dermatologics Presents An Analysis Of SILIQ™ (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
Summary of Results
Effects of Brodalumab on Anxiety and Depression in Patients With Psoriasis: Results From a Phase 3, Randomized, Controlled Clinical Trial
Results from the Phase 3, randomized, controlled clinical trial AMAGINE-1 suggested that treatment with SILIQ reduced anxiety and depression in patients with moderate-to-severe plaque psoriasis. In the study, hospital anxiety and depression scale (HADS) scores were measured at baseline and at 12, 24, 36 and 52 weeks in patients treated with SILIQ (210 mg) or placebo. After 12 weeks of SILIQ treatment, patients experienced a decrease in depression and anxiety HADS scores (mean scores decreased by 2.1 and 1.8, respectively) while scores remained unaffected in those receiving placebo. Improvement in depression and anxiety HADS scores were also seen in patients who switched from placebo to SILIQ after a 12 week induction phase (mean scores decreased by 2.3 and 1.7, respectively), but worsened in patients who switched from SILIQ to placebo.
Long-term Safety of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: 2-Year Data From 3 Pivotal Phase 3 Clinical Trials
Results from a pooled analysis of three double-blind, placebo-controlled, Phase 3 clinical trials (AMAGINE-1, -2, and -3) demonstrated that the safety profile of SILIQ in patients with moderate-to-severe plaque psoriasis during the second year of treatment was similar to that of the first year of treatment. Additionally, no unexpected safety signals emerged. The analysis evaluated 3,708 patients who received any dose of SILIQ in the long-term, open-label extension studies of the three trials. Overall, in the second year of treatment, the most common treatment-emergent adverse events were joint pain (n=196), headache (n=155) and candida infections (n=111), and one fatal treatment-emergent adverse event (cardiac arrest) occurred.
Eigentlich müßte das Black Label nun entfallen!
Valeant Pharmaceuticals Intl Inc.: Get Ready for a Massive Opportunity
https://www.fool.ca/2018/02/14/valeant-pharmaceuticals-intl-… 17.05.24 · Accesswire · Bausch Health Companies |
15.05.24 · Accesswire · Bausch Health Companies |
14.05.24 · Accesswire · Bausch Health Companies |
09.05.24 · Accesswire · Bausch Health Companies |
02.05.24 · Accesswire · Bausch Health Companies |
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
11.04.24 · Accesswire · Bausch Health Companies |
11.04.24 · Accesswire · Bausch Health Companies |
03.04.24 · Accesswire · Bausch Health Companies |
02.04.24 · Accesswire · Bausch Health Companies |